Shares of Cortexyme Inc. (NASDAQ:CRTX) traded at a new 52-week high today of $124.30. So far today approximately 23.1 million shares have been exchanged, as compared to an average 30-day volume of 463,000 shares.
Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains. The company operates in only one reportable segment that is developing and commercializing therapeutics.
In the past 52 weeks, shares of Cortexyme Inc. have traded between the current low of $3.69 and a high of $121.98 and is now at $5.30.
There is potential upside of 2.9% for shares of Cortexyme Inc. based on a current price of $5.30 and an average consensus analyst price target of $5.45.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer